IP Library › Granted Patent US 11,166,912
Granted Patent B2
US 11,166,912 · App. 15/059,444 · Granted Nov 9, 2021

Orally administrable composition

Inventor: Pankaj Modi (Ancaster, CA)
Assignee: CTT Pharma Inc.
A61K9/1075A61K9/006A61K9/0053A61K9/7007A61K31/05A61K31/352A61K31/4468A61K31/485
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,166,912
App. No.
15/059,444
Granted
Nov 9, 2021
Kind
B2
Abstract

An orally administrable micellar composition is provided. The composition comprises a pharmaceutical agent encapsulated in micelles formed by at least one micelle-forming compound in a pharmaceutically acceptable aqueous solvent comprising an alkali metal salicylate and a pharmaceutically acceptable edetate combined with at least one physiologically acceptable film forming agent.

Claims (14)

1. An orally administrable composition in the form of a wafer comprising: i) at least one physiologically acceptable film forming agent in an amount ranging from about 30 to 80% by wt. in a pharmaceutically acceptable aqueous solvent combined with ii) a micellar composition comprising a cannabinoid encapsulated in micelles of 50-1000 nm in size formed by micelle-forming compounds, in a pharmaceutically acceptable aqueous solvent, wherein the at least one physiologically acceptable film forming agent comprises pullulan, and the micelle-forming compounds comprise sodium lauryl sulfate, a bile acid and glycerine, and wherein the wafer is formed by applying cycles of heating and cooling.

2. The orally administrable composition of claim 1 , wherein the composition further comprises one or more micelle-forming compounds selected from the group consisting of polyoxyethylene ethers, esters or alcohols; phosphatidylcholine; lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, chamomile extract, cucumber extract, menthol, trihydroxy oxo cholanylglycine, polyglycerin, lysine, polylysine, triolein, polidocanol alkyl ethers, and mixtures thereof.

3. The orally administrable composition of claim 2 , further comprising a micelle-forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, polyglycerin, lysine, polylysine, triolein and mixtures thereof.

4. The orally administrable composition of claim 1 , wherein each micelle-forming compound, and an isotonic agent, are present in an amount in the range of from 1 to 10 wt./wt. % of the total composition, and the total amount of the micelle-forming compounds and the isotonic agent is less than 50 wt./wt. % of the composition.

5. The orally administrable composition of claim 1 , wherein the cannabinoid is selected from the group consisting of cannabidiol (CBD), cannabidiol acid (CBDA), cannabinol (CBN), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabidivarin acid (CBDVA), cannabinovarin (CBNV), cannabigerovarin (CBGV) and cannabichromene (CBC), delta-9 tetrahydrocannabinol (THC), delta-8 tetrahydrocannabinol (D8-THC), tetrahydrocannabinol acid (THCA), tetrahydrocannabivarin (THCV), tetrahydrocannabivarin acid (THCVA), and mixtures thereof.

6. The orally administrable composition of claim 1 , wherein the at least one physiologically acceptable film forming agent comprises pullulan and an additional film forming agent selected from the group consisting of methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, methacrylic acid polymers, methacrylic acid copolymers, acrylic acid polymers, acrylic acid copolymers, polyacrylamides, polyalkylene oxides, carrageanan, polyvinyl alcohol, sodium alginate, polyethylene glycol, polyacrylic acid, glycolide, polylactide, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, alginic acid, pea starch, dextrin, pectin, chitin, chitosan, levan, elsinan and mixtures thereof.

7. The orally administrable composition of claim 6 , wherein the additional film forming agent is selected from the group consisting of xanthan gum, tragacanth gum, guar gum, locust bean gum, acacia gum, arabic gum, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof.

8. The orally administrable composition of claim 6 , wherein the at least one physiologically acceptable film forming agent comprises a mixture of pullulan with one or more additional film forming agents selected from polyvinyl alcohol, carrageenan, guar gum, xanthan gum and locust bean gum.

9. The orally administrable composition of claim 6 , additionally comprising one or more of: a plasticizing agent, a flavoring agent, a sulfur precipitating agent, a saliva stimulating agent, a cooling agent, a surfactant, a stabilizing agent, an emulsifying agent, a thickening agent, a binding agent, a coloring agent, a sweetener, and a fragrance.

10. The orally administrable composition of claim 1 , wherein the composition exhibits a Tmax of the cannabinoid on administration to a patient of less than about 7 minutes.

11. A method of preparing the orally administrable composition of claim 1 comprising the cannabinoid of claim 1 , comprising the steps of: i) mixing the cannabinoid in a solvent together with the micelle-forming compounds of claim 1 , with an isotonic agent, to form a micellar composition, wherein the total amount of the micelle-forming compounds, and the isotonic agent, is less than 50 wt./wt. % of the composition; and iii) combining the micellar composition with the at least one physiologically acceptable film forming agent, pullulan, in an aqueous solvent to form a gel, spreading the gel into a thin layer and allowing the gel to set, by applying cycles of heating and cooling.

12. The orally administrable composition of claim 1 , wherein the micelles are of a size within the range of about 50 to 500 nm.

13. The orally administrable composition of claim 1 , wherein the bile acid is selected from the group consisting of cholic acid, deoxycholic acid, glycocholic acid, chenodeoxycholic acid, taurocholic acid, glycodeoxycholic acid, taurodeoxycholic acid, salts thereof and mixtures thereof.

14. The method of claim 11 , wherein the at least one physiologically acceptable film forming agent comprises a mixture of pullulan with one or more additional film forming agents selected from polyvinyl alcohol, carrageenan, guar gum, xanthan gum and locust bean gum.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017
From: MODI, PANKAJ
To: CTT PHARMA INC.
Reel/Frame 041761/0538 →
Continuity (1)
Related Publication 20170252300A1 · Sep 7, 2017